Marella Thorell's departure as Chief Financial Officer of Seres Therapeutics, Inc. was reported, effective November 15, 2026; the filing names no successor. As of November 6, 2026, Seres Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 1, 2026 to October 26, 2026, naming 1 departure (Form 8-K, October 26, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Seres Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Seres Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-01 to 2026-10-26. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Seres Therapeutics, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-26 | Out | Chief Financial Officer | 2026-11-15 | 8-K, 2026-10-26 | |
| 2026-06-01 | Reported | not named in the filing | 8-K, 2026-06-01 |
Selling to them or working with them? See who runs Seres Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Watch Seres Therapeutics, Inc.
Get an email when Seres Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Seres Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Seres Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Seres Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Seres Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Marella Thorell, departure reported, effective 2026-11-15 (filed 2026-10-26). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Seres Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Seres Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Seres Therapeutics, Inc.Every change, in the filing's words
Departing: Marella Thorell, Chief Financial Officer, effective 2026-11-15
On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the "Company"), resigned from her positions as Executive Vice President and Chief Financial Officer of the Company, effective November 15, 2026 (the "Effective Date").
- Following the Effective Date, Ms. Thorell is expected to provide advisory services to the Company to support an orderly transition, on terms to be agreed between Ms. Thorell and the Company.
Reported
On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the "Company") and on the committees on which he serves, effective May 31, 2026.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
- Dr. Woerle's departure is not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Tools for this story
Each opens in a new tab, filled in for Seres Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.